Clinical Study
Obinutuzumab: A Study Drug for People with Membranous Nephropathy
Membranous Nephropathy (MN) is a rare kidney disease. Obinutuzumab is an approved drug for some cancers. It is a study drug to help people with MN. Research is needed to learn the safety and effectiveness of the study drug compared with the approved drug tacrolimus. The information we learn will aid future patients.
For more information contact:
Inge Stijleman
inge.stijleman@hsc.utah.edu
8012131368
IRB#: IRB_00148974
| PI: Josephine Abraham
| Department: NEPHROLOGY ADMINISTRATION
| Approval Date: 2022-10-05 06:00:00
Specialties: Nephrology & Hypertension
Who can participate?
Gender: All
Age: Under 7 or over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria:
- Ages 18-75
- MN diagnosis
- No major surgery
- No history of serious infection
- In-person at University of Utah
Exclusion Criteria:
- Type 1 or 2 diabetes
- History of cancer in the past 5 years
- Current alcohol or drug abuse
- Other causes of MN such as specific autoimmune diseases, Hepatitis B, Hepatitis C, and HIV
- Pregnant
Will I be paid for my time?
Yes